Zydus Receives Positive USFDA Compliance Update for Ahmedabad Oncology Plant

has received a positive regulatory boost as the USFDA reclassified its oncology injectable facility at SEZ-1, Ahmedabad from Official Action Indicated (OAI) to Voluntary Action Indicated (VAI), following a GMP follow-up inspection held between June 9–18, 2025. This marks an important step in strengthening compliance at a key export-oriented plant. Alongside this, its subsidiary ZyVet recently launched FDA-approved generics for urinary incontinence and heart failure in pets, expanding its footprint in veterinary healthcare. Earlier this month, Zydus also completed a USFDA inspection at its Jarod injectable site, which resulted in four observations, none linked to data integrity with the company taking corrective action. These developments signal steady progress in regulatory compliance and product diversification. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.